RTW RTW Venture Fund

Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

Edison Investment Research Limited
Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

12-Jan-2022 / 08:05 GMT/BST


 

London, UK, 12 January 2021

 

RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from business formations through to investing in much larger listed biotech and medtech companies. RTW is focused on identifying and developing next-generation therapies to significantly improve patients' lives. Since launch, RTWVF's number of investments in private companies has accelerated and the manager is very excited by the global opportunities available.

 

RTWVF provides investors with broad exposure to the global biotech (c 85% of the fund) and medtech (c 15%) sectors. Since inception in late October 2019, the fund has outpaced the performance of both small- and large-cap biotech indices. Its approach of being science-based and a full lifecycle investor, including early-stage, means that the manager is constantly adding to its knowledge bank. RTWVF is prepared to build businesses around attractive assets and supports investee companies as they mature, via a range of financing options. Holdings in private companies are often maintained following their initial public offerings (IPOs) to ensure maximum value is realised, while RTWVF also invests in companies that are already public. RTW has announced it is setting up regional offices in the UK and Shanghai, which should broaden the fund's opportunity set.


to view the full report or to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 

Sarah Godfrey +44 (0)20 3077 5700 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1267706  12-Jan-2022 

fncls.ssp?fn=show_t_gif&application_id=1267706&application_name=news&site_id=research_pool
EN
12/01/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RTW Venture Fund

Pedro Fonseca
  • Pedro Fonseca

RTW Biotech Opportunities - Termination of coverage

Edison Investment Research is terminating coverage on RTW Biotech Opportunities (RTW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

 PRESS RELEASE

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant...

Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 1 November 2023   Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed...

Pedro Fonseca
  • Pedro Fonseca

RTW Biotech Opportunities - Significant acquisition of Arix Bioscience...

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive ne...

Pedro Fonseca
  • Pedro Fonseca

RTW Biotech Opportunities - Use of Prometheus Biosciences’ sale procee...

In June 2023, RTW Biotech Opportunities (RTWBIO) changed its name from RTW Venture Fund to more accurately reflect the company’s full life cycle approach to biotech investing. On 5 July 2023, RTWBIO announced its capital allocation plans for the proceeds received from Merck’s acquisition of Prometheus Biosciences which, when announced, was the company’s largest holding at 14.8% of NAV. The acquisition price was a 75.4% premium to the pre-bid level. Prometheus is a good example of RTW’s long-term...

Pedro Fonseca
  • Pedro Fonseca

RTW Venture Fund Limited - Finding value in the out-of-favour biotech ...

RTW Venture Fund (RTWVF) is focused on innovative biotech and medtech businesses that have clear pathways to delivering approved medicines and medical technologies to patients. It is managed by RTW Investments (RTW), a New York-headquartered, life sciences investment firm with offices in London and Shanghai. RTW takes a science-led, full-lifecycle approach to investing in both public and private opportunities, supporting companies at all stages of development via multiple capital solutions. Biot...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch